Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

GERN – Geron Corporation

Geron Corporation
GERN
$1.02
Name : Geron Corporation
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $657,123,584.00
EPSttm : -0.08
finviz dynamic chart for GERN
Geron Corporation
$1.02
4.70%
$0.046
GERN — Price & Float Short
—— Fair value ★ EPS beat ★ EPS miss —— Target Price
Float Short %

Float Short %

10.54

Margin Of Safety %

Put/Call OI Ratio

0.27

EPS Next Q Diff

EPS Last/This Y

0.11

EPS This/Next Y

0.11

Price

1

Target Price

3.5

Analyst Recom

1.4

Performance Q

-33.55

Upside

-340.2%

Beta

0.6

Ticker: GERN




22 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2026-10-13GERN1.2050.2810.7973173
2026-10-14GERN1.1850.280.0573593
2026-10-15GERN1.2250.280.7773909
2026-10-16GERN1.1750.280.0274059
2026-10-19GERN1.1950.290.0670256
2026-10-20GERN1.230.290.1070313
2026-10-21GERN1.150.290.0470337
2026-10-22GERN1.1250.280.1171121
2026-10-23GERN1.1150.280.2671309
2026-10-26GERN1.150.280.1771774
2026-10-27GERN1.140.280.1971982
2026-10-28GERN0.96590.280.5372114
2026-10-29GERN0.94150.290.6074184
2026-10-30GERN0.89310.290.1674330
2026-11-02GERN0.92950.270.0275086
2026-11-03GERN0.93670.270.0975738
2026-11-04GERN1.0750.270.0576021
2026-11-05GERN0.95010.270.0076271
2026-11-06GERN0.98780.270.0676308
2026-11-09GERN0.99050.270.2976246
2026-11-10GERN0.97190.270.0076285
2026-11-11GERN1.0050.270.0176119
DateSymbolLatestP/C OIP/C VolTotal OI
22 items Current Page1 of 1




22 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2026-10-13GERN1.2166.763.9-0.02
2026-10-14GERN1.1966.764.1-0.02
2026-10-15GERN1.2366.765.2-0.02
2026-10-16GERN1.1766.762.9-0.02
2026-10-19GERN1.2066.765.0-0.02
2026-10-20GERN1.2066.765.0-0.02
2026-10-21GERN1.2466.765.8-0.02
2026-10-22GERN1.1266.763.8-0.02
2026-10-23GERN1.1266.763.8-0.02
2026-10-26GERN1.1566.765.8-0.02
2026-10-27GERN1.1466.764.6-0.02
2026-10-28GERN0.9766.758.9-0.02
2026-10-29GERN0.9566.763.7-0.02
2026-10-30GERN0.8966.762.4-0.02
2026-11-02GERN0.93- 66.0-0.04
2026-11-03GERN0.94- 66.3-0.04
2026-11-04GERN1.08- 70.1-0.04
2026-11-05GERN0.95- 43.0-0.04
2026-11-06GERN0.99- 47.6-0.04
2026-11-09GERN0.99- 46.2-0.04
2026-11-10GERN0.97- 45.3-0.04
2026-11-11GERN1.00- 47.3-0.02
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
22 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2026-10-13GERN0.00-0.1411.67
2026-10-14GERN0.00-0.1411.67
2026-10-15GERN0.00-0.1411.67
2026-10-16GERN0.00-0.1411.67
2026-10-19GERN0.00-0.1711.67
2026-10-20GERN0.00-0.1711.67
2026-10-21GERN0.00-0.1711.67
2026-10-22GERN0.00-0.1711.67
2026-10-23GERN0.00-0.1711.67
2026-10-26GERN0.00-0.7711.67
2026-10-27GERN0.00-0.7711.78
2026-10-28GERN0.00-0.7711.78
2026-10-29GERN0.00-0.7711.78
2026-10-30GERN0.00-0.7711.78
2026-11-02GERN0.00-0.9211.78
2026-11-03GERN0.00-0.9211.78
2026-11-05GERN0.00-0.9211.78
2026-11-06GERN0.00-0.9211.78
2026-11-09GERN0.00-1.6011.75
2026-11-10GERN0.00-1.6011.75
2026-11-11GERN0.00-1.6010.54
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

0.01

Avg. EPS Est. Next Quarter

0.01

Insider Transactions

Institutional Transactions

-1.6

Beta

0.6

Average Sales Estimate Current Quarter

65

Average Sales Estimate Next Quarter

75

Fair Value

Quality Score

53

Growth Score

47

Sentiment Score

84

Actual DrawDown %

81.3

Max Drawdown 5-Year %

-82.4

Target Price

3.5

P/E

Forward P/E

14.17

PEG

P/S

3.02

P/B

2.9

P/Free Cash Flow

EPS

-0.07

Average EPS Est. Cur. Y​

-0.02

EPS Next Y. (Est.)

0.09

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-23.04

Relative Volume

0.54

Return on Equity vs Sector %

-47.5

Return on Equity vs Industry %

-27.9

EPS 1 7Days Diff

EPS 1 30Days Diff

0.02

EBIT Estimation

47.3
◆ GERN Healthcare
$1.02
📉
Swing / Pullback
Buy the dip on strong trends
N/A
0 /100
WEAK
Trend
0/20
Pullback
13/25
Volume
11/15
Valuation
15/20
TP/AR
4/10
Options
8/10
RSI
44.3
Range 1M
38.8%
Sup Dist
8.3%
🚀
Momentum Growth
Ride accelerating trends
N/A
37 /100
WEAK
Momentum
0/25
Growth
25/30
Estimates
4/20
Inst/Vol
0/15
Options
8/10
EPS Yr
78.5%
EPS NY
357.1%
52W%
13.3%
💎
Long-Term Value
Quality companies, undervalued
N/A
0 /100
WEAK
🟢 BUY +218.6% upside
Quality
6/30
Valuation
18/30
Growth
18/25
Stability
5/10
LT Trend
1/5
Upside
+218.6%
Quality
53
GERN — P/E HistoricalBiotechnology
Geron Corporation
Sector: Healthcare
Industry: Biotechnology
Employees: 258
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML. Geron Corporation was incorporated in 1990 and is headquartered in Foster City, California.
GERN

Latest News

—
Caricamento notizie per GERN…
stock quote shares GERN – Geron Corporation Stock Price stock today
news today GERN – Geron Corporation stock forecast ,stock prediction 2023 2024 2025
marketwatch GERN – Geron Corporation yahoo finance google finance
stock history GERN – Geron Corporation invest stock market
stock prices GERN premarket after hours
ticker GERN fair value insiders trading